Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Tiziana Life Sciences Ltd (NQ: TLSA ) 0.9200 -0.0201 (-2.14%) Streaming Delayed Price Updated: 3:59 PM EDT, Sep 4, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 75,192 Open 0.9500 Bid (Size) 0.9100 (1) Ask (Size) 1.020 (7) Prev. Close 0.9401 Today's Range 0.9100 - 0.9624 52wk Range 0.4100 - 1.740 Shares Outstanding 194,612,289 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Tiziana Life Sciences Appoints New Chief Executive Officer August 19, 2024 From Tiziana Life Sciences Ltd. Via GlobeNewswire Tiziana Life Sciences Regains Compliance with Nasdaq Listing Minimum Bid Price Rule August 14, 2024 From Tiziana Life Sciences Ltd. Via GlobeNewswire Performance YTD +61.38% +61.38% 1 Month -9.80% -9.80% 3 Month -8.91% -8.91% 6 Month +91.63% +91.63% 1 Year +21.21% +21.21% More News Read More The 3 Best EV Stocks to Buy in August 2024 August 10, 2024 Via InvestorPlace Tiziana Life Sciences Granted FDA Fast Track Designation July 24, 2024 From Tiziana Life Sciences Ltd. Via GlobeNewswire Tiziana Receives $3.4 Million in Non-Dilutive Funding June 28, 2024 From Tiziana Life Sciences Ltd. Via GlobeNewswire Tiziana Life Sciences adds to treasury with $3.4 million in non-dilutive funding June 28, 2024 Via News Direct Tiziana Life Sciences to Dose First Patient with Moderate Alzheimer’s Disease with Foralumab June 26, 2024 From Tiziana Life Sciences Ltd. Via GlobeNewswire 12 Health Care Stocks Moving In Monday's After-Market Session June 17, 2024 Via Benzinga Global Multiple Sclerosis Drugs Market Size Projected to Reach $38 Billion By 2032 as Demand on R&D for Developing Innovative Drugs Rises June 11, 2024 Via FinancialNewsMedia Exposures Product Safety FDA Accepts Tiziana Life Sciences Fast Track Designation Submission for Treatment of Multiple Sclerosis June 11, 2024 From Tiziana Life Sciences Ltd. Via GlobeNewswire Global Multiple Sclerosis Drugs Market Size Projected to Reach $38 Billion By 2032 as Demand on R&D for Developing Innovative Drugs Rises June 11, 2024 From FN Media Group LLC Via GlobeNewswire 12 Health Care Stocks Moving In Friday's After-Market Session June 07, 2024 Via Benzinga Tiziana Life Sciences Announces Six-Month Qualitative Improvement in Neuroimaging in 80% of Multiple Sclerosis Patients Receiving Intranasal Foralumab June 06, 2024 From Tiziana Life Sciences Ltd. Via GlobeNewswire Tiziana Life Sciences Submits Grant Application to ALS Association to Fund Clinical Trial of Intranasal Foralumab June 04, 2024 From Tiziana Life Sciences Ltd. Via GlobeNewswire Tiziana Life Sciences Scientific Board Chairman to Receive Prestigious Award for Multiple Sclerosis Research May 30, 2024 From Tiziana Life Sciences Ltd. Via GlobeNewswire EXCLUSIVE: Top Tesla Options Trades Recommended By Trading Expert May 15, 2024 Via Benzinga Tiziana Life Sciences Files for Orphan Drug Designation for Intranasal Foralumab May 13, 2024 From Tiziana Life Sciences Ltd. Via GlobeNewswire Tiziana Life Sciences Reports Positive 3-Month Neuroimaging Scores in Multiple Sclerosis Patients Receiving Intranasal Foralumab April 25, 2024 From Tiziana Life Sciences Ltd. Via GlobeNewswire Why Tesla Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket April 24, 2024 Via Benzinga 12 Health Care Stocks Moving In Tuesday's After-Market Session April 23, 2024 Via Benzinga 12 Health Care Stocks Moving In Tuesday's Pre-Market Session April 23, 2024 Via Benzinga Tiziana Life Sciences Announces FDA Allowance for Additional Twenty Patients to be Enrolled in the Intranasal Foralumab Multiple Sclerosis Expanded Access Program April 23, 2024 From Tiziana Life Sciences Ltd. Via GlobeNewswire Tiziana Life Sciences Announces Additional Clinical Improvements Among Multiple Sclerosis Patients in its Expanded Access Program April 22, 2024 From Tiziana Life Sciences Ltd. Via GlobeNewswire 12 Health Care Stocks Moving In Friday's After-Market Session April 19, 2024 Via Benzinga Tiziana Life Sciences Announces Study Results from Intranasal Anti-CD3 Foralumab in Multiple Sclerosis Patients with PIRA Highlighted in Neurology Today® April 19, 2024 From Tiziana Life Sciences Ltd. Via GlobeNewswire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.